NAFLD 피험자에서 LivPhcD 캡슐의 효능 및 안전성 평가
NAFLD 피험자에서 LivPhcD 캡슐의 효능 및 안전성을 평가하기 위한 다중 센터, 무작위, 이중 맹검, 위약 대조 연구
Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse. Early-stage NAFLD does not usually cause any harm but nonalcoholic steatohepatitis (NASH) can lead to serious liver damage, including fibrosis or cirrhosis. Nearly 25% of the world's population is affected by NAFLD.
There are no FDA-approved medications for the treatment of NAFLD currently and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients.
LivPhcD™ capsule have shown hepatoprotective effects in both animal and human data. This study aims to investigate the effects of LivPhcD™ capsule in hepatocellular lipid content using Fibroscan.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Not Required For This Country
-
Taipei, Not Required For This Country, 대만, 221
- National Taiwan University Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female between 20 and 75 years of age.
- Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
- Has a body mass index (BMI) ≥20 kg/m^2 and ≤50 kg/m^2 and stable weight for the past 3 months
- CAP ≥ 238 db/m
- Fibro scan (transient elastography) F0~F3
Exclusion Criteria:
- Pregnant or breastfeeding or planning to become pregnant or unwilling to use an acceptable contraceptive method to avoid pregnancy during the study period
- Type 1 diabetes mellitus.
- History of other causes of chronic liver disease [autoimmune, primary biliary cirrhosis, HBV (HBsAg positive) and HCV, Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.
- Use of medications that could induce steatosis, such as estrogen or other hormonal replacement therapy, amiodarone, methotrexate, tamoxifen, raloxifene, pharmacological doses of oral glucocorticoids (≥10 mg per day of prednisone or equivalent), or chloroquine.
- Use of vitamin E (doses ≥800 IU/dy) or pioglitazone or SGLT2 inhibitor or GLP-1 agonists any FDA-approved drug for NASH to be approved during the study.
- Has significant systemic or major illnesses other than liver disease, ex: recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, serious COPD, renal failure and need hemodialysis, stroke, transient ischemic attack, or organ transplantation
- Known alcohol abuse or alcohol use disorder (>20 g/day for women; >30 g/day for men)
- Has the abnormal data including: fasting TG >400 mg/dL ; ALT or GGT>5.0 x ULN;Bilirubin >2 x ULN,unless due to an alternative etiology such as Gilbert's syndrome; INR ≥1.3; Albumin < LLN; Platelet <0.95x LLN
- Subjects with hemoglobin A1c (HbA1c) >8.5% within 3 months before study entry
- Plan to have major surgery during the study period (bariatric surgery, biliary diversion surgery)
- Participation in any other investigational clinical trial within 30 days of entry to this protocol(including drugs, medical devices, novel medical technologies, food, and lifestyle interventions affecting diet, exercise, and circadian rhythm investigational clinical trial.);
- History of HIV
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Placebo without active ingredient |
Placebo matching LivPhcD cap. |
|
활성 비교기: 2 cap.LivPhcD/per day
515mg/LivPhcD cap. 2 cap./per day |
2 caps. LivPhcD cap. after meal, once a day |
|
활성 비교기: 4 cap.LivPhcD/per day
515mg/LivPhcD cap. 4 cap./per day, BID |
4 caps. LivPhcD cap. after meal, BID |
|
활성 비교기: 6 cap.LivPhcD/per day
515mg/LivPhcD cap. 6 cap./per day, TID |
6 caps. LivPhcD cap. after meal, TID |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Reduction of Liver Fat
기간: 36 weeks
|
Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fat by CAP(Controlled Attenuation Parameter) |
36 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in liver fat at least 30% reduction
기간: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with ≥ 30% reduction of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fat at least 1 stage reduction
기간: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fat
기간: 24 weeks and 36 weeks
|
Between group difference in mean change of liver fat by CAP |
24 weeks and 36 weeks
|
|
Stable in liver fat
기간: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with stable of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fibrosis at least 10% reduction
기간: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Change in liver fibrosis at least 1 stage reduction
기간: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Stable in liver fibrosis
기간: 24 weeks and 36 weeks
|
Between group difference in the proportion of patients with stable reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Change in liver fibrosis
기간: 24 weeks and 36 weeks
|
Between group difference in mean change of FIB-4 |
24 weeks and 36 weeks
|
|
Change in ALT
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of ALT |
24 weeks and 36 weeks
|
|
Change in AST
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of AST |
24 weeks and 36 weeks
|
|
Change in GGT
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of GGT |
24 weeks and 36 weeks
|
|
Change in AP
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of AP |
24 weeks and 36 weeks
|
|
Change in Bilirubin
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Bilirubin |
24 weeks and 36 weeks
|
|
Change in Triglyceride
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Triglyceride |
24 weeks and 36 weeks
|
|
Change in Total Cholesterol
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Total Cholesterol |
24 weeks and 36 weeks
|
|
Change in HDL-C
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of HDL-C |
24 weeks and 36 weeks
|
|
Change in LDL-C
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of LDL-C |
24 weeks and 36 weeks
|
|
Change in TNF-α
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of TNF-α |
24 weeks and 36 weeks
|
|
Change in C-Reactive Protein
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of C-Reactive Protein |
24 weeks and 36 weeks
|
|
Change in Albumin
기간: 24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Albumin |
24 weeks and 36 weeks
|
|
Occurrence of adverse events and serious adverse events
기간: 24 weeks and 36 weeks
|
Between group difference in the occurrence of adverse events and serious adverse events. |
24 weeks and 36 weeks
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- LivPhcD-001
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .